Sorry missed this post before
As one of the largest and successful shareholders it is normal for the company to reach out to Klump. Many on the bod were large shareholders first. He gives up a lot though when going from shareholder to board of directors. Before he could have quietly sold at any point and filed at the start of the following year after he had sold. Now he would have to report any stock selling within two business days and can’t sell when he has non-disclosed information like he would know with partnership knowledge. So basically he showed he was going to the finish line.
Has he helped? Here is his own words of how he planned on helping. Without insider info, we probably will not know how much he helped until we reach the finish line. I’m sure he has brought in connections, some probably already invented in the previous offering, and ideas that we will learn about later... maybe these institutions/banks NP keeps talking about.
“The appointment of Michael to our Board is aligned with this expanded focus that we announced in July of 2018. Michael brings extensive capital markets expertise to our Board, and I am pleased to welcome him as our newest director. We look forward to calling upon Michael’s experience in raising capital and evaluating transactions as CytoDyn seeks to realize the value of PRO 140 across a variety of therapeutic opportunities.”
“Having been invested in CytoDyn for over two years, I’ve seen first-hand the incredible promise PRO 140 offers to patients suffering from a variety of life-threatening diseases,” said Mr. Klump. “I’m excited to be joining the Board at this important moment when greater emphasis will be placed on the commercialization of PRO 140. I am hopeful that my experience guiding previous companies through capital raising and growth initiatives will be an asset as CytoDyn looks to maximize shareholder value over the coming years.”
Mr. Klump has nearly 30 years of financial experience and has been actively involved in formulating and executing strategic financial plans. He founded Argonne Capital Group, LLC (“Argonne”), a private investment firm, in 2003. Since inception, Argonne has invested over $750 million of equity in public and private companies spanning multiple industries. In all instances, Argonne looks for opportunities where the firm can leverage its management infrastructure and capabilities to help its portfolio companies with a variety of initiatives, including strategic planning, acquisitions and capital raising. Mr. Klump received a Bachelor of Arts from the University of Colorado in 1987.
Quote:also raised the question several times about Klump, what is his purpose for being on the board
As one of the largest and successful shareholders it is normal for the company to reach out to Klump. Many on the bod were large shareholders first. He gives up a lot though when going from shareholder to board of directors. Before he could have quietly sold at any point and filed at the start of the following year after he had sold. Now he would have to report any stock selling within two business days and can’t sell when he has non-disclosed information like he would know with partnership knowledge. So basically he showed he was going to the finish line.
Has he helped? Here is his own words of how he planned on helping. Without insider info, we probably will not know how much he helped until we reach the finish line. I’m sure he has brought in connections, some probably already invented in the previous offering, and ideas that we will learn about later... maybe these institutions/banks NP keeps talking about.
“The appointment of Michael to our Board is aligned with this expanded focus that we announced in July of 2018. Michael brings extensive capital markets expertise to our Board, and I am pleased to welcome him as our newest director. We look forward to calling upon Michael’s experience in raising capital and evaluating transactions as CytoDyn seeks to realize the value of PRO 140 across a variety of therapeutic opportunities.”
“Having been invested in CytoDyn for over two years, I’ve seen first-hand the incredible promise PRO 140 offers to patients suffering from a variety of life-threatening diseases,” said Mr. Klump. “I’m excited to be joining the Board at this important moment when greater emphasis will be placed on the commercialization of PRO 140. I am hopeful that my experience guiding previous companies through capital raising and growth initiatives will be an asset as CytoDyn looks to maximize shareholder value over the coming years.”
Mr. Klump has nearly 30 years of financial experience and has been actively involved in formulating and executing strategic financial plans. He founded Argonne Capital Group, LLC (“Argonne”), a private investment firm, in 2003. Since inception, Argonne has invested over $750 million of equity in public and private companies spanning multiple industries. In all instances, Argonne looks for opportunities where the firm can leverage its management infrastructure and capabilities to help its portfolio companies with a variety of initiatives, including strategic planning, acquisitions and capital raising. Mr. Klump received a Bachelor of Arts from the University of Colorado in 1987.
1
